Disaggregated Revenues

12 Months Ended

Dec. 31, 2022

Disaggregation of Revenue [Abstract]

Disaggregated Revenues

Disaggregated Revenues

The following table summarizes the disaggregation of revenues by product or source (dollars in thousands):

	Years Ended December 31,
	2022		2021		2020
Net product sales
Trokendi XR	$	261,221	$	304,817	$	319,640
Oxtellar XR	115,345		110,708		98,725
GOCOVRI	104,421		9,778		—
APOKYN	75,305		99,233		74,296
Qelbree	61,322		9,879		—
Other(1)	31,818		33,089		16,689
Total net product sales	649,432		567,504		509,350
Royalty revenues	17,806		12,271		11,047
Total revenues	$	667,238	$	579,775	$	520,397

______________________________

(1) Includes net product sales of MYOBLOC, XADAGO and Osmolex ER.

Trokendi XR accounted for more than 40% of the Company's total net product sales in 2022, more than 50% in 2021, and more than 60% in 2020.

The Company recognized noncash royalty revenues of $9.8 million, $9.4 million, and $8.5 million for the years ended December 31, 2022, 2021, and 2020, respectively, consequent to the Company's agreement with HC Royalty (see Note 2, Summary of Significant Accounting Policies).

Adjustments related to prior year sales in 2022 and 2021 have amounted to less than 1% of net product sales for each of the respective periods. Adjustments related to prior year sales in 2020 was $13.8 million compared to net product sales of $509.4 million in 2020. This included a $10.7 million adjustment for the discontinued Trokendi XR commercial blister pack configuration.